Jonathan Faison
Seeking Alpha
Contact Jonathan
Discover and connect with journalists and influencers around the world, save time on email research, monitor the news, and more.
| Recent: |
|
| Past: |
|
Past articles by Jonathan:
Inozyme Pharma: Rare Disease Player Merits Revaluation Higher After POC Data (NASDAQ:INZY)
Inozyme shares are down 58% over the past year. Read why the company's enzyme replacement therapy is an attractive area of drug development. → Read More
Rain Oncology: Multiple Data Catalysts In 2023 For This Precision Oncology Pioneer (RAIN)
Rain Oncology shares have fallen by nearly 40% since 2021 IPO. Read more here. → Read More
AVITA Medical: Experienced CEO Taking The Helm As Expansion Opportunities Await
AVITA Medical shares have fallen by 83% over the past 3 years and are down 13% over the past year. See why I rate RCEL stock a strong buy. → Read More
Fate Therapeutics Stock: iPSC Pioneer A Buy For Long-Term Investors
Fate Therapeutics' shares have fallen by over 80% during the past 12 months. Read more to see why I think FATE stock is a Buy for long-term investors only. → Read More
Avidity Biosciences: Proof-Of-Concept Achieved In DM1 For AOC Platform (NASDAQ:RNA)
Avidity seeks to tackle a fundamental challenge in the RNA space, namely delivery outside the liver via AOC platform technology. See why the stock is a Buy. → Read More
Eton Pharmaceuticals: Alkindi Sprinkle Leads Growth In Orphan Disease Portfolio
Eton Pharmaceuticals' Alkindi Sprinkle is their lead orphan product, addressing a $100M opportunity. Click here to read why ETON stock is a Buy. → Read More
Nkarta (NKTX): A Buy On Pullback With Valuation At Lows
Nkarta is a Buy due to valuation alone, which is likely to rebound next year as key catalysts approach. Read more here. → Read More
ImmunoGen Needs To Make The Most Of Its First-Mover Opportunity (NASDAQ:IMGN)
ImmunoGen's Elahere recently received accelerated approval in FRα-high, platinum-resistant ovarian cancer and sports first-mover advantage. Read why IMGN is a Buy. → Read More
Longboard Pharmaceuticals: Arena Team's Next Act Is Flying Under The Radar
Longboard Pharmaceuticals is a Buy. Key concerns include near term dilution, binary risk as a single drug story and low trading volume. Read my analysis on LBPH. → Read More
UroGen Pharma: Jelmyto Sales Growing Steadily, Concerns Remain (URGN)
UroGen Pharma shares have lost nearly two-thirds of their value over the past 3 years. See why URGN stock is a buy at current levels. → Read More
Axsome Therapeutics: All Eyes On Auvelity Launch
Shares of Axsome Therapeutics have posted a 30% gain so far in 2022. Read more to understand why this stock needs to be watched. → Read More
Y-mAbs Therapeutics: Future Upside Dependent On Reinvigorating Danyelza Sales
Shares have lost 45% in 2022 and are down by 58% since my 2019 article. Conservative peak sales estimate of $200M vs, current enterprise value of $260M. → Read More
Scholar Rock: OLE Data In SMA Coupled With New CEO Make It A Buy
Scholar Rock shares have lost over 20% of their value during the past 3 years and are down 70% so far in 2022. Click here to find out why SRRK is a Buy. → Read More
Immunovant Stock: Capitalizing On Fast Growing FcRn Space With Novel Asset (NASDAQ:IMVT)
Shares have lost roughly half their value since arriving on the Nasdaq in late 2019 via SPAC. See why IMVT is a Buy and I suggest initiating a pilot position in the near term. → Read More
ORIC Pharmaceuticals (ORIC) Stock: Poster Child For The Current Downturn In Biotech
ORIC is a speculative Buy. Key risks include disappointing data for phase 1 readouts 1H23, delays in the clinic and heavy competition in certain areas. Read more. → Read More
IDEAYA Biosciences: Prospects Rebound With Updated Uveal Melanoma Data (NASDAQ:IDYA)
IDEAYA Biosciences stock has posted a 40% loss over the past 12 months. But click here to know the reasons why IDYA is still a Buy. → Read More
Arcutis Biotherapeutics: Keeping A Close Eye On Launch Metrics For Zoryve (NASDAQ:ARQT)
Arcutis Biotherapeutics' shares are down 15% year to date. Read more to see why ARQT stock is a buy for long-term investors. → Read More
Cullinan Oncology: Modality-Agnostic Approach To Yield Fruit In Coming Years (NASDAQ:CGEM)
Patient investors with a multi-year timeframe should consider Cullinan Oncology. Click here for a full investment analysis of CGEM stock. → Read More
Aadi Bioscience: Taking mTOR Inhibition To The Next Level (NASDAQ:AADI)
Aadi Bioscience shares lost half their value since reverse merger with Aerpio Pharmaceuticals. Click here to read why AADI stock is a Buy in my view. → Read More
Aldeyra Therapeutics: Dry Eye Is Just The Beginning For Novel MOA (NASDAQ:ALDX)
At the current valuation, the market is more optimistic about Aldeyra's approach to RASP and prospects for lead program reproxalap. Click here to see why ALDX is a Buy. → Read More